{
    "clinical_study": {
        "@rank": "106057", 
        "brief_summary": {
            "textblock": "Objective:\n\n      Glutamate-based medications including the N-methyl-D-aspartate (NMDA) receptor antagonist\n      ketamine result in rapid, robust and sustained (up to one week) antidepressant effects in\n      randomized controlled trials in treatment-refractory unipolar and bipolar depression.\n      Previous work by our group has demonstrated that a family history of alcohol dependence\n      predicts a more robust antidepressant response to ketamine in both treatment-resistant\n      unipolar and bipolar depression.\n\n      Recently-detoxified alcoholics and affected first-degree relatives display blunted\n      psychotomimetic, cognitive and other neuropsychiatric effects with a subanesthetic dose of\n      ketamine.  Also, a family history of alcoholism alone predicts differential response to\n      intravenous alcohol.  Based on our prior post hoc results, we seek to prospectively\n      demonstrate that a family history of alcohol dependence predicts a more robust\n      antidepressant response to ketamine.  We will also explore potential biomarkers of ketamine\n       s antidepressant effects in treatment-refractory depressed patients at risk of alcohol\n      dependence (using physiological and neurochemical responses to alcohol).\n\n      Study Population:\n\n      21-65 year old treatment-resistant major depressive disorder without psychotic features\n      patients in a current major depressive episode of at least moderate severity will be\n      recruited and enrolled in this protocol.  All subjects must also be free of a lifetime\n      substance use disorder diagnosis with the exception of a nicotine or caffeine use disorder)\n      and will be psychotropic medication-free for at least two weeks prior to the first alcohol\n      infusion.  Our targeted number of completers will be 50 depressed subjects (60 signing\n      consent to account for attrition): 25 FHP subjects [as defined by either one first degree\n      relative or two second-degree relatives with alcohol dependence on the Family Interview for\n      Genetics Studies (FIGS) and Family Tree Questionnaire (FTQ)] and 25 FHN negative subjects.\n\n      Design:\n\n      This study is a single-site, open-label protocol in psychotropic medication-free depressed\n      subjects admitted to the Clinical Research Center   s Mood and Anxiety Disorder Inpatient\n      Research Unit (7-SE).  This protocol consists of two phases (Phase I and Phase II). The\n      first phase consists of the medication taper and drug-free period.  The second phase will\n      have three subphases: Subphase IIA (   alcohol clamp    infusion #1 with neurophysiological\n      assessments), IIB (   alcohol clamp    infusion #2 during 7 Tesla-Magnetic Resonance\n      Spectroscopy/Imaging (7T-MRS/I)) and IIC (subanesthetic/antidepressant dose ketamine\n      infusion during 7T-MRS/I).\n\n      Outcome Measures:\n\n      The primary hypothesis/outcome measure will be change in mean Montgomery-Asberg Depression\n      Rating Scale (MADRS) total score from the pre-ketamine infusion baseline-to-7 days\n      post-infusion between the FHP and FHN groups.  Other exploratory measures include\n      neurophysiological responses to intravenous alcohol infusion, brain neurochemical\n      alterations during intravenous alcohol infusion, brain neurochemical alterations during\n      intravenous ketamine infusion and resting state (task-free) functional magnetic resonance\n      imaging as a function of family history of an alcohol use disorder."
        }, 
        "brief_title": "The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Magnetic Resonance Imaging", 
            "Major Depression", 
            "Alcoholism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alcoholism", 
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objective:\n\n      Glutamate-based medications including the N-methyl-D-aspartate (NMDA) receptor antagonist\n      ketamine result in rapid, robust and sustained (up to one week) antidepressant effects in\n      randomized controlled trials in treatment-refractory unipolar and bipolar depression.\n      Previous work by our group has demonstrated that a family history of alcohol dependence\n      predicts a more robust antidepressant response to ketamine in both treatment-resistant\n      unipolar and bipolar depression.\n\n      Recently-detoxified alcoholics and affected first-degree relatives display blunted\n      psychotomimetic, cognitive and other neuropsychiatric effects with a subanesthetic dose of\n      ketamine.  Also, a family history of alcoholism alone predicts differential response to\n      intravenous alcohol.  Based on our prior post hoc results, we seek to prospectively\n      demonstrate that a family history of alcohol dependence predicts a more robust\n      antidepressant response to ketamine.  We will also explore potential biomarkers of ketamine\n       s antidepressant effects in treatment-refractory depressed patients at risk of alcohol\n      dependence (using physiological and neurochemical responses to alcohol).\n\n      Study Population:\n\n      21-65 year old treatment-resistant major depressive disorder without psychotic features\n      patients in a current major depressive episode of at least moderate severity will be\n      recruited and enrolled in this protocol.  All subjects must also be free of a lifetime\n      substance use disorder diagnosis with the exception of a nicotine or caffeine use disorder)\n      and will be psychotropic medication-free for at least two weeks prior to the first alcohol\n      infusion.  Our targeted number of completers will be 50 depressed subjects (60 signing\n      consent to account for attrition): 25 FHP subjects [as defined by either one first degree\n      relative or two second-degree relatives with alcohol dependence on the Family Interview for\n      Genetics Studies (FIGS) and Family Tree Questionnaire (FTQ)] and 25 FHN negative subjects.\n\n      Design:\n\n      This study is a single-site, open-label protocol in psychotropic medication-free depressed\n      subjects admitted to the Clinical Research Center   s Mood and Anxiety Disorder Inpatient\n      Research Unit (7-SE).  This protocol consists of two phases (Phase I and Phase II). The\n      first phase consists of the medication taper and drug-free period.  The second phase will\n      have three subphases: Subphase IIA (   alcohol clamp    infusion #1 with neurophysiological\n      assessments), IIB (   alcohol clamp    infusion #2 during 7 Tesla-Magnetic Resonance\n      Spectroscopy/Imaging (7T-MRS/I)) and IIC (subanesthetic/antidepressant dose ketamine\n      infusion during 7T-MRS/I).\n\n      Outcome Measures:\n\n      The primary hypothesis/outcome measure will be change in mean Montgomery-Asberg Depression\n      Rating Scale (MADRS) total score from the pre-ketamine infusion baseline-to-7 days\n      post-infusion between the FHP and FHN groups.  Other exploratory measures include\n      neurophysiological responses to intravenous alcohol infusion, brain neurochemical\n      alterations during intravenous alcohol infusion, brain neurochemical alterations during\n      intravenous ketamine infusion and resting state (task-free) functional magnetic resonance\n      imaging as a function of family history of an alcohol use disorder."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA:\n\n          -  21 to 65 years of age.\n\n          -  A level of understanding sufficient to agree to all required tests and examinations,\n             sign an informed consent document and verify understanding by a score greater than or\n             equal to 90% on the consent quiz.\n\n          -  DSM-IV-TR diagnosis of MDD, single-episode (296.30) or recurrent (296.20) without\n             psychotic features based on clinical assessment and confirmed by a Structured\n             Clinical Interview for the DSM-IV- Patient Version (SCID-P). Subjects must be\n             experiencing a current major depressive episode of at least 2 weeks duration.\n\n          -  Past failure of greater than or equal to two standard antidepressant trial based on\n             the Antidepressant Treatment History Form (ATHF).\n\n          -  MADRS score greater than or equal to 20 at baseline and the day of ketamine infusion.\n\n        EXCLUSION CRITERIA:\n\n          -  Inadequate knowledge of family mental and substance use history, e.g. adoption.\n\n          -  Current psychotic features or prior diagnosis of a DSM-IV-TR psychotic spectrum\n             disorder, e.g. schizophrenia, schizoaffective disorder, bipolar I disorder with\n             psychotic features, MDD with psychotic features, or bipolar disorder, e.g. bipolar I\n             disorder without psychotic features, bipolar II disorder and bipolar disorder not\n             otherwise specified (NOS).\n\n          -  Lifetime history of DSM-IV-TR drug or alcohol use disorder (except for caffeine or\n             nicotine dependence), currently seeking or have a prior history of seeking help for\n             alcohol problems, non-drinkers (no alcohol in the past year) and history of\n             alcohol-induced flushing reactions.\n\n          -  Pregnant or nursing women or women of child bearing potential not using at least one\n             medically accepted means of contraception (to include oral, injectable, or implant\n             birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal\n             ligation, abstinence or partner with vasectomy).\n\n          -  Serious, unstable medical conditions/problems including hepatic, renal,\n             gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic,\n             immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled\n             hyper/hypothyroidism or active cancer.\n\n          -  Presence of any medical illness likely to alter brain morphology and/or physiology\n             (e.g., hypertension, diabetes) even if controlled by medications.\n\n          -  Clinically significant abnormal laboratory tests.\n\n          -  Subjects with one or more seizures without clear and resolved etiology and head\n             injury with loss of consciousness for >  5 minutes or requiring hospitalization.\n\n          -  Treatment with psychiatric medications, e.g. selective serotonin reuptake inhibitors,\n             serotonin norepinephrine reuptake inhibitors, benzodiazepines and antipsychotics, at\n             least two weeks of study phase II\n\n          -  Treatment with fluoxetine within 4 weeks of study phase II.\n\n          -  Treatment with device-based treatment for depression, e.g. electroconvulsive therapy\n             (ECT), transcranial magnetic stimulation (TMS) and vagal nerve stimulation (VNS),\n             within 4 weeks of study phase II.\n\n          -  Lifetime history of deep brain stimulation.\n\n          -  Treatment with any disallowed concomitant medications.\n\n          -  Positive HIV test\n\n          -  Presence of ferromagnetic implants, e.g, heart pacemaker or aneurysm clip, or other\n             contraindications to magnetic resonance imaging (MRI), e.g. claustrophobia or hearing\n             loss.\n\n          -  Clinically-significant anatomical brain abnormalities detected on routine brain MRI.\n\n          -  Subjects who, in the investigator   s judgment, pose a current serious suicidal or\n             homicidal risk, or who have a MADRS item 10 score of > 4.\n\n        Additionally, the Investigators may exclude or terminate any patient for clinical reasons."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122562", 
            "org_study_id": "140085", 
            "secondary_id": "14-M-0085"
        }, 
        "intervention": [
            {
                "description": "Treatment", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Biomarker", 
                "intervention_name": "Alcohol Infusion", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethanol", 
                "Ketamine", 
                "Antidepressive Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ketamine", 
            "Major Depression", 
            "Alcohol", 
            "Alcohol Clamp", 
            "NMDA Antagonist"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2014-M-0085.html"
        }, 
        "location": {
            "contact": {
                "email": "prpl@mail.cc.nih.gov", 
                "last_name": "For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)", 
                "phone": "800-411-1222", 
                "phone_ext": "TTY8664111010"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder", 
        "overall_contact": {
            "email": "alex.noury@nih.gov", 
            "last_name": "Alex J Noury", 
            "phone": "(301) 496-9848"
        }, 
        "overall_contact_backup": {
            "email": "zaratec@mail.nih.gov", 
            "last_name": "Carlos A Zarate, M.D.", 
            "phone": "(301) 451-0861"
        }, 
        "overall_official": {
            "affiliation": "National Institute of Mental Health (NIMH)", 
            "last_name": "Carlos A Zarate, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total MADRS score", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to seven days post infusion"
        }, 
        "reference": [
            {
                "PMID": "10686270", 
                "citation": "Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4."
            }, 
            {
                "PMID": "16894061", 
                "citation": "Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64."
            }, 
            {
                "PMID": "21232924", 
                "citation": "Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011 Feb 28;191(2):122-7. doi: 10.1016/j.pscychresns.2010.10.009. Epub 2011 Jan 12."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Neurophysiological measures during alcohol challenge, e.g. baseline grooved pegboard performance", 
                "safety_issue": "No", 
                "time_frame": "first alcohol infusion"
            }, 
            {
                "measure": "AANts, e.g. baseline/intra-alcohol and ketamine infusion 1H-MRS detectable glutamate", 
                "safety_issue": "No", 
                "time_frame": "during second alcohol and detamine infusions"
            }
        ], 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Mental Health (NIMH)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}